OBJECTIVES: To assess the clinical and economic burden of Alzheimer’s disease in the U.S. veteran population. METHODS:  Data from the Veterans Health Administration (VHA) Medical SAS Datasets was used to conduct a retrospective study (October 1, 2005 - May 31, 2012). Patients diagnosed with Alzheimer’s disease throughout the study period were identified using International Classification of Disease 9thRevision Clinical Modification (ICD-9-CM) diagnosis code 331.0. Health care resource utilization and costs were assessed in the 12-month follow-up period, and clinical status was examined for the 12-month baseline period before disease identification. Major treatments during the 60 days after disease identification were also studied. All descriptive statistical analyses were performed using SAS v9.3 software. RESULTS: A total of 54,161 Alzheimer’s disease patients were identified in the VHA population during the study period. The most common comorbidities for Alzheimer’s disease patients were hypertension (n=14,387, 26.56%), followed by mental disorders (n=13,440, 24.81%), diabetes (n=7,440, 13.74%) and memory loss (n=4,850, 8.95%). Other comorbidities included senile dementia and hearing loss. The top three treatments for Alzheimer’s disease were donepezil hydrochloride (n=16,526, 30.51%), simvastatin (n=16,010, 29.56%), and memantine (n=11,081, 20.46%). Outpatient services were utilized by 98.62% of Alzheimer’s patients, followed by pharmacy (86.75%) and inpatient visits (30.29%).  Outpatient ($7,650, [standard deviation] SD=$12,539), pharmacy ($1,660, SD=$2,688), and inpatient costs ($16,790, SD=$75,963) contributed to follow-up health care expenditures. CONCLUSIONS: The U.S. veteran Alzheimer’s disease patient population had high percentages of comorbid conditions, including hypertension and mental disorders, as well as outpatient and inpatient visits. Further analysis is needed to evaluate the extent to which the treatment of Alzheimer’s disease is complicated by the presence of these comorbidities.